Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer

European Journal of Cancer

Volumn 48, Issue 9, 2012, Pages 1283-1292

  Maraveyas, A ^a,i   Waters, J ^b   Roy, R ^c   Fyfe, D ^d   Propper, D ^e   Lofts, F ^f   Sgouros, J ^a,g   Gardiner, E ^a   Wedgwood, K ^a   Ettelaie, C ^h   Bozas, G ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b Kent Oncology Centre   (United Kingdom)

^c DIANA PRINCESS OF WALES HOSPITAL   (United Kingdom)

^d ROYAL LANCASTER INFIRMARY   (United Kingdom)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^g Agioi Anargiroi Hospital   (Greece)

^h UNIVERSITY OF HULL   (United Kingdom)

ⁱ UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Anticoagulation; Dalteparin; Pancreatic cancer; Thrombosis

Indexed keywords

DALTEPARIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN ISCHEMIA; CANCER PATIENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG FATALITY; DRUG WITHDRAWAL; EPISTASIS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HUMAN; INCIDENCE; INFECTION; KIDNEY DYSFUNCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PANCREAS CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN BRUISING; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTIMETABOLITES, ANTINEOPLASTIC; DALTEPARIN; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; SURVIVAL RATE; VENOUS THROMBOEMBOLISM;

EID: 84861334022     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.10.017     Document Type: Article

References (25)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics CA Cancer J Clin 59 4 2009 225 249
2. Cancer Research UK. Pancreatic cancer statistics - key facts. Available from: http://info.cancerresearchuk.org/cancerstats/keyfacts/pancreatic-cancer/.
3. D.R. Xie, H.L. Liang, Y. Wang, S.S. Guo, and Q. Yang Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone World J Gastroenterol 12 43 2006 6973 6981
4. A.A. Khorana, and R.L. Fine Pancreatic cancer and thromboembolic disease Lancet Oncol 5 11 2004 655 663
5. H.K. Chew, T. Wun, D. Harvey, H. Zhou, and R.H. White Incidence of venous thromboembolism and its effect on survival among patients with common cancers Arch Intern Med 166 4 2006 458 464
6. J.W. Blom, S. Osanto, and F.R. Rosendaal High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients Eur J Cancer 42 3 2006 410 414
7. J.W. Blom, C.J. Doggen, S. Osanto, and F.R. Rosendaal Malignancies, prothrombotic mutations, and the risk of venous thrombosis JAMA 293 6 2005 715 722
8. M. Mandala, M. Reni, and S. Cascinu Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients Ann Oncol 18 10 2007 1660 1665
9. A. Maraveyas, and M. Johnson Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Br J Cancer 100 12 2009 1837 1841
10. A. Maraveyas, M. Holmes, and F. Lofts Chemoanticoagulation versus chemotherapy in advanced pancreatic cancer (APC): results of the interim analysis of the FRAGEM trial J Clin Oncol 25 2007 ASCO Annual Meeting Proceedings Part I, 18S (June 20 Suppl.) 2007 4583
11. H.A. Burris 3rd, M.J. Moore, and J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 1997 2403 2413
12. A.Y. Lee, M.N. Levine, and R.I. Baker Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 2 2003 146 153
13. A. Maraveyas, J. Waters, and R. Roy Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study) Eur J Cancer Suppl 7 2 2009 362
14. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
15. H.F. Hillen Thrombosis in cancer patients Ann Oncol 11 Suppl. 3 2000 273 276
16. W.M. Hryniuk, and M. Goodyear The calculation of received dose intensity J Clin Oncol 8 12 1990 1935 1937
17. G. Agnelli, G. Gussoni, and C. Bianchini Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study Lancet Oncol 10 10 2009 943 949
18. A.K. Kakkar, M.N. Levine, and Z. Kadziola Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) J Clin Oncol 22 10 2004 1944 1948
19. K. Sideras, P.L. Schaefer, and S.H. Okuno Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial Mayo Clin Proc 81 6 2006 758 767
20. J. Sgouros, and A. Maraveyas Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer Acta Oncol 47 3 2008 337 346
21. F. Icli, H. Akbulut, and G. Utkan Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer J Surg Oncol 95 6 2007 507 512
22. H. Riess, U. Pelzer, and B. Opitz A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial J Clin Oncol 28 15 Suppl. 2010 [abstr. 4033]
23. H.T. Sorensen, E. Horvath-Puho, L. Pedersen, J.A. Baron, and P. Prandoni Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study Lancet 370 9601 2007 1773 1779
24. M. Zawin, C. Camputaro, and Z. Rahman CT multirow detector CT detection of subclinical visceral and pulmonary thrombosis in advanced pancreatic cancer is an adverse prognostic indicator Proc Am Soc Clin Oncol 22 2003 [abstr. 1419]
25. M.W. Reynolds, A. Shibata, and S. Zhao Impact of clinical trial design and execution-related factors on incidence of thromboembolic events in cancer patients: a systematic review and meta-analysis Curr Med Res Opin 24 2 2008 497 505